Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure… Jan 11, 2022
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use… Jan 11, 2022
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling… Jan 10, 2022
Liquid Meta Announces Appointment of Blockchain Expert Clara Bullrich to Board of Directors Jan 10, 2022
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program… Jan 6, 2022
MariMed Announces Agreement to Acquire Kind Therapeutics USA, LLC, A Maryland Licensed Vertically Integrated Cannabis… Jan 5, 2022
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral… Jan 5, 2022
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook Jan 5, 2022
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic… Jan 5, 2022
